Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorFujian Cancer Hospital
About this trial
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).
Eligibility criteria
Qualifiers
Patients with multiple metastases at first diagnosis or multiple metastases after treatment(multiple metastases were defined as more than 5 lesions and/or more than 2 metastasis organs); Histologically or cytologically confirmed multiple metastatic NPC.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at trial entry, and life expectancy ≥ 6 months as judged by the Investigator;
The disease must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Adequate organ function;
Take adequate contraceptive measures throughout the study, and contraception continues until 12 months after treatment;
Disqualifiers
Patients with a hypersensitivity to any of the drugs used in our study;
With any active autoimmune disease or history of autoimmune disease;
Clinically significant cardiovascular and cerebrovascular diseases;
Have or are suffering from other malignant tumors within 5 years (except non-melanoma skin cancer or pre-invasive cervical cancer);
Trial design
Treatments tested in this trial
- Gemcitabine
- Cisplatin
- Paclitaxel protein-bound
- Capecitabine
- Tislelizumab
Treatment groups
39 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov